Published in
Elsevier, The Lancet Oncology, 10(13), p. 1045-1054, 2012
DOI: 10.1016/s1470-2045(12)70346-7
Links
Tools
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
Journal article published in 2012 by
Penella J. Woll 
,
Peter Reichardt,
Axel Le Cesne,
Sylvie Bonvalot,
Alberto Azzarelli,
Harald J. Hoekstra,
Michael G. Leahy,
Frits Van Coevorden,
Jaap Verweij,
Pancras Cw Hogendoorn,
Monia Ouali,
Sandrine Marreaud,
Vivien Hc C. Bramwell,
Peter Hohenberger
,
Peter Reichardt,
Axel Le Cesne,
Sylvie Bonvalot,
Alberto Azzarelli,
Harald J. Hoekstra,
Michael G. Leahy,
Frits Van Coevorden,
Jaap Verweij,
Pancras Cw Hogendoorn,
Monia Ouali,
Sandrine Marreaud,
Vivien Hc C. Bramwell,
Peter Hohenberger
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
The effect of adjuvant chemotherapy on survival for resected soft-tissue sarcoma remains unknown. We investigated the effect of intensive adjuvant chemotherapy on survival in patients after resection of high-risk soft-tissue sarcomas.